Beaver Run Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
- Meeting Program
- Meeting Summary
- Abstract Information
- Registration Information
- Scholarships / Awards
- Lodging / Hotels
- Travel / Transportation
- Conference Location
- Things to Do
- Services
- My Account
NOTES:
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
Download Flyer
Twitter hashtag for this meeting: #KSimmtherapy
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
Download Flyer
Twitter hashtag for this meeting: #KSimmtherapy
Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity (B3)
Scientific Organizers: Daniel J. Cua, E. John Wherry and Carla V. Rothlin
February 18—22, 2019
Beaver Run Resort, Breckenridge, Colorado, USA
Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.
Organized in collaboration with Cancer Research UK
Sponsored by AbbVie Inc., BioLegend, Inc., Compass Therapeutics, EMD Serono Research and Development Institute, Inc., Genentech, Inc., Incyte Corporation, MacroGenics, Inc., Merck & Co., Inc., MorphoSys AG, Pfizer Inc., Roche, Surface Oncology, Takeda Pharmaceutical Company Limited and Tessa Therapeutics Ltd.
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
DEADLINES:Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: Oct 23, 2018 [details]
Discounted Abstract Deadline: Oct 23, 2018 [details]
Abstract Deadline: Nov 15, 2018 [details]
Discounted Registration Deadline: Dec 18, 2018 [details]
If you have missed a deadline due to the US government shutdown, please contact our office.
Click here to view Cancellation Policy
Discounted Abstract Deadline: October 23, 2018
*All deadlines end at 11:59 PM US Mountain Standard TimeAbstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register
Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract early allows us to:
- submit your abstract to organizers to be considered for a short talk
- accept your abstract online
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
(The Abstract Deadline: is November 15, 2018)
Global Health Travel Award Deadline:
*All deadlines end at 11:59 PM US Mountain Standard Time
Global Health Travel Award Details:
You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline
and complete the other required steps (verify your contact information and submit a recommendation letter)
to be considered for a travel award.
Click here to learn more about Global Health Travel Awards.
Scholarship Deadline: October 23, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Details:
You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.
Abstract Deadline: November 15, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register
Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract by the Abstract Deadline allows us to:
- submit your abstract to organizers to be considered for a short talk
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.
(Discounted Abstract Deadline: is October 23, 2018)
Discounted Registration Deadline: December 18, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Registration Fee: 845.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
After the Discounted Registration Deadline:
Registration Fee: 1045.00 USD*
Student Registration Fee: 820.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
Registration spaces are limited and may fill prior to discounted registration deadline.
Please be advised that some meeting participants have received calls and emails from a number of different housing services,
including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED
WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting
is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a
lodging reservation with them.
We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Monday, February 18 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Friday, February 22 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Saturday, February 23 in order to fully experience the meeting.
MONDAY, FEBRUARY 18
TUESDAY, FEBRUARY 19
WEDNESDAY, FEBRUARY 20
THURSDAY, FEBRUARY 21
FRIDAY, FEBRUARY 22
SATURDAY, FEBRUARY 23
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Monday, February 18 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Friday, February 22 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Saturday, February 23 in order to fully experience the meeting.
MONDAY, FEBRUARY 18
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
*
Daniel J. Cua,
Merck Research Laboratories, USA
09:00—11:15
Checkpoint Blockade Predisposes Patients to Autoimmunity
Registered attendees can view abstracts starting on 01/18/2019
Registered attendees can view abstracts starting on 01/18/2019
*
E. John Wherry,
University of Pennsylvania, USA
Jeffrey A. Bluestone,
University of California, San Francisco, USA
Development of Syngeneic NOD Tumor Models to Study Tumor Immunity in Autoimmune-Prone Mice
Development of Syngeneic NOD Tumor Models to Study Tumor Immunity in Autoimmune-Prone Mice
Coffee Break
Jennifer Ann Wargo,
University of Texas MD Anderson Cancer Center, USA
Immune Mechanisms Influencing Checkpoint Therapy
Immune Mechanisms Influencing Checkpoint Therapy
Dario A. A. Vignali,
University of Pittsburgh School of Medicine, USA
Regulation of Autoimmunity and Cancer by PD1 and LAG3
Regulation of Autoimmunity and Cancer by PD1 and LAG3
Soyoung Oh,
Genentech, Inc., USA
Short Talk: PD-L1 Expression by Dendritic Cells is a Critical Checkpoint in the Regulation of T Cell Immunity
Short Talk: PD-L1 Expression by Dendritic Cells is a Critical Checkpoint in the Regulation of T Cell Immunity
17:00—19:00
Genetics of Autoimmunity and Cancer: What are the Common Denominators?
Registered attendees can view abstracts starting on 01/18/2019
Registered attendees can view abstracts starting on 01/18/2019
*
Jennifer Ann Wargo,
University of Texas MD Anderson Cancer Center, USA
Alex Marson,
University of California, San Francisco, USA
Reprogramming Human Immune Cell Circuitry
Reprogramming Human Immune Cell Circuitry
Elissa K. Deenick,
Garvan Institute of Medical Research, Australia
Signals Controlling Lymphocyte Activation and Autoimmunity - Lessons from Inborn Errors of Immunity
Signals Controlling Lymphocyte Activation and Autoimmunity - Lessons from Inborn Errors of Immunity
Wenjun Ouyang,
Amgen, Inc., USA
Lessons from Human Genetics for Autoimmunity and Cancer Therapy
Lessons from Human Genetics for Autoimmunity and Cancer Therapy
Zia Khan,
Genentech, Inc., USA
Short Talk: Genetic Risk for Skin Autoimmunity Impacts the Safety and Efficacy of Immune Checkpoint Blockade in Urothelial Carcinoma
Short Talk: Genetic Risk for Skin Autoimmunity Impacts the Safety and Efficacy of Immune Checkpoint Blockade in Urothelial Carcinoma
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Cellular Reprogramming: Regulatory vs. Functional Fate
Registered attendees can view abstracts starting on 01/18/2019
Registered attendees can view abstracts starting on 01/18/2019
*
Susan M. Kaech,
The Salk Institute, USA
Alexander Y. Rudensky,
HHMI/Memorial Sloan Kettering Cancer Center, USA
Treg Stability in Disease
Treg Stability in Disease
Mark S. Anderson,
University of California, San Francisco, USA
Modulating Self-Tolerance in Autoimmunity and Cancer
Modulating Self-Tolerance in Autoimmunity and Cancer
Coffee Break
Maria Grazia Roncarolo,
Stanford University School of Medicine, USA
Regulatory T Cell Therapy in Cancer and Autoimmunity
Regulatory T Cell Therapy in Cancer and Autoimmunity
Eric Meffre,
Yale University School of Medicine, USA
Impaired B Cell Tolerance and Autoimmunity: CTLA-4 Blockade Dirty Secret
Impaired B Cell Tolerance and Autoimmunity: CTLA-4 Blockade Dirty Secret
Theodore T. Drashansky,
University of Florida, USA
Short Talk: Epigenetic Landscape Dictated by Bcl11b Sustains Treg Cell Program while Blocking Innate Lineage and Apoptosis
Short Talk: Epigenetic Landscape Dictated by Bcl11b Sustains Treg Cell Program while Blocking Innate Lineage and Apoptosis
Sophie Lucas,
de Duve Institute, Belgium
Short Talk: Structural Basis of Latent TGF-β1 Presentation and Activation by GARP on Human Regulatory T Cells
Short Talk: Structural Basis of Latent TGF-β1 Presentation and Activation by GARP on Human Regulatory T Cells
14:30—16:30
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapies
*
Soyoung Oh,
Genentech, Inc., USA
Peter V. Kharchenko,
Harvard Medical School, USA
Molecular Impact of Prostate Cancer Metastasis on the Bone Marrow Microenvironment
Molecular Impact of Prostate Cancer Metastasis on the Bone Marrow Microenvironment
Kasey L. Couts,
University of Colorado Denver, USA
Differential Gene Expression Across Melanoma Subtypes Predicts Responses to Immune Checkpoint Blockade
Differential Gene Expression Across Melanoma Subtypes Predicts Responses to Immune Checkpoint Blockade
Yannick Simoni,
Fred Hutchinson Cancer Research Center, USA
Identification of Tumor-Specific CD8+ T Cells in EBV Driven Lymphoephitelioma-Like Carcinoma: A Case Report
Identification of Tumor-Specific CD8+ T Cells in EBV Driven Lymphoephitelioma-Like Carcinoma: A Case Report
Colt Egelston,
City of Hope, USA
Identification of Tumor Inflammation Associated Exhausted CD8+ T Cells in Breast Cancer Patients
Identification of Tumor Inflammation Associated Exhausted CD8+ T Cells in Breast Cancer Patients
Alexander Huang,
University of Pennsylvania, USA
Clinical and Immunologic Activity of a Single Dose of Neoadjuvant PD-1 Blockade and Predictors of Clinical Outcomes in Resectable Melanoma
Clinical and Immunologic Activity of a Single Dose of Neoadjuvant PD-1 Blockade and Predictors of Clinical Outcomes in Resectable Melanoma
Debattama Sen,
Harvard Medical School, USA
Functionally Specialized Subsets of Exhausted CD8+ T Cells Mediate Tumor Control and Differentially Respond to Checkpoint Blockade
Functionally Specialized Subsets of Exhausted CD8+ T Cells Mediate Tumor Control and Differentially Respond to Checkpoint Blockade
*
Krijn Dijkstra,
Netherlands Cancer Institute, Netherlands
Generation of Tumor-Reactive T Cells by Co-Culture of Peripheral Blood Lymphocytes and Tumor Organoids
Generation of Tumor-Reactive T Cells by Co-Culture of Peripheral Blood Lymphocytes and Tumor Organoids
Martina Damo,
Yale University, USA
A New Mouse Model to Investigate Tissue-Specific Aspects of Peripheral T Cell Tolerance
A New Mouse Model to Investigate Tissue-Specific Aspects of Peripheral T Cell Tolerance
17:00—19:00
Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell Lineages
Registered attendees can view abstracts starting on 01/18/2019
Registered attendees can view abstracts starting on 01/18/2019
*
Dario A. A. Vignali,
University of Pittsburgh School of Medicine, USA
E. John Wherry,
University of Pennsylvania, USA
T Cell Exhaustion and Fate Decisions – Implications for Immunotherapy
T Cell Exhaustion and Fate Decisions – Implications for Immunotherapy
Ian A. Parish,
Peter MacCallum Cancer Centre, Australia
Phenotypically and Functionally Defining CD8+ T Cell Tolerance versus Exhaustion
Phenotypically and Functionally Defining CD8+ T Cell Tolerance versus Exhaustion
Shin Foong Ngiow,
University of Pennsylvania, USA
Short Talk: Lag3 Represses Cytotoxicity Program to Facilitate CD8 T Cell Exhaustion
Short Talk: Lag3 Represses Cytotoxicity Program to Facilitate CD8 T Cell Exhaustion
Kristen Elaine Pauken,
Harvard Medical School, USA
Short Talk: Deletion of PD-1 Promotes Anti-Tumor Immunity Through Cell Intrinsic and Extrinsic Improvements in CD8+ T Cell Metabolism and Functions
Short Talk: Deletion of PD-1 Promotes Anti-Tumor Immunity Through Cell Intrinsic and Extrinsic Improvements in CD8+ T Cell Metabolism and Functions
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Registered attendees can view abstracts starting on 01/18/2019
Registered attendees can view abstracts starting on 01/18/2019
*
Catherine Hedrick,
La Jolla Institute for Allergy and Immunology, USA
Carla V. Rothlin,
Yale University, USA
Coincidence Detectors in Macrophages and Tissue Repair
Coincidence Detectors in Macrophages and Tissue Repair
Coffee Break
Ming O. Li,
Memorial Sloan Kettering Cancer Center, USA
Deconstructing the Antigen-Presenting Cell Compartment in Cancer
Deconstructing the Antigen-Presenting Cell Compartment in Cancer
Fiona M. Powrie,
University of Oxford, UK
Inflammation Driven Cancer: Host and Microbial Pathways
Inflammation Driven Cancer: Host and Microbial Pathways
Hind Medyouf,
Institute for Tumor Biology and Experimental Therapy, Germany
Short Talk: Targeting TAM Receptors Unleashes Anti-Leukemic Immunity and Enables Checkpoint Blockade Leading to Eradication of Leukemic Cells
Short Talk: Targeting TAM Receptors Unleashes Anti-Leukemic Immunity and Enables Checkpoint Blockade Leading to Eradication of Leukemic Cells
Sergei Grivennikov,
Fox Chase Cancer Center, USA
Short Talk: Cell Type Specific Role of Cytokines in Control of Tumor Promoting Inflammation and Tumor Bacterial Invasion
Short Talk: Cell Type Specific Role of Cytokines in Control of Tumor Promoting Inflammation and Tumor Bacterial Invasion
14:30—16:30
Workshop 2: Latest Developments on the Role of Myeloid Cells in Inflammation and Cancer
*
Hind Medyouf,
Institute for Tumor Biology and Experimental Therapy, Germany
Yemsratch T. Akalu,
Yale University School of Medicine, USA
An eMERerging Target in Cancer Immunotherapy
An eMERerging Target in Cancer Immunotherapy
Joanne Tan,
Arcus Biosciences, USA
Targeting Innate Immune Cells for the Treatment of Cancer
Targeting Innate Immune Cells for the Treatment of Cancer
Tal Burstyn-Cohen,
Hebrew University Jerusalem, Israel
Myeloid-Derived PROS1 Inhibits Tumor Metastasis by Curbing Inflammation
Myeloid-Derived PROS1 Inhibits Tumor Metastasis by Curbing Inflammation
Chang-Yu Chen,
Tokyo University of Science, Japan
An Alarmin HMGN1 Synergizes with PD-L1 Blockade and CD4 Depletion to Reinforce CD8 T Cell-Mediated Anti-Tumor Immunity
An Alarmin HMGN1 Synergizes with PD-L1 Blockade and CD4 Depletion to Reinforce CD8 T Cell-Mediated Anti-Tumor Immunity
*
Kelsey Sivick Gauthier,
Aduro Biotech, Inc., USA
Magnitude of Therapeutic STING Activation Critically Impacts CD8+ T Cell-Mediated Anti-Tumor Immunity
Magnitude of Therapeutic STING Activation Critically Impacts CD8+ T Cell-Mediated Anti-Tumor Immunity
Karen Hastings,
University of Arizona College of Medicine, Phoenix, USA
High GILT Expression and An Active and Functional MHC Class II Antigen Presentation Pathway are Associated with Improved Survival in Melanoma
High GILT Expression and An Active and Functional MHC Class II Antigen Presentation Pathway are Associated with Improved Survival in Melanoma
Emma Lo Kuan,
Benaroya Research Institute, USA
Thymic Stromal Lymphopoietin Promotes Interplay Between Tumor Cells, Myeloid Cells, and CD8+ T Cells in Regulation of Breast Cancer
Thymic Stromal Lymphopoietin Promotes Interplay Between Tumor Cells, Myeloid Cells, and CD8+ T Cells in Regulation of Breast Cancer
Rachel S. Friedman,
National Jewish Health and University of Colorado, Denver, USA
Mononuclear Phagocytes Drive a Mertk-Dependent Tolerance Checkpoint at the Autoimmune Disease Site
Mononuclear Phagocytes Drive a Mertk-Dependent Tolerance Checkpoint at the Autoimmune Disease Site
17:00—19:00
Neutrophils and MDSCs in Host Defense and Cancer
Registered attendees can view abstracts starting on 01/18/2019
Registered attendees can view abstracts starting on 01/18/2019
*
Carla V. Rothlin,
Yale University, USA
Catherine Hedrick,
La Jolla Institute for Allergy and Immunology, USA
Neutrophil Heterogeneity in Cancer
Neutrophil Heterogeneity in Cancer
Dmitry I. Gabrilovich,
Wistar Institute, USA
Neutrophils and PMN-MDSC in Cancer: Two Sides of Functional Diversity
Neutrophils and PMN-MDSC in Cancer: Two Sides of Functional Diversity
James T. Nevin,
University of Connecticut Health Center, USA
Sympathetic Nervous Tone Influences Accumulation of Myeloid-Derived Suppressor Cells and Immune Control of Tumor Growth
Sympathetic Nervous Tone Influences Accumulation of Myeloid-Derived Suppressor Cells and Immune Control of Tumor Growth
Eynav Klechevsky,
Washington University School of Medicine, USA
Upstream Regulation of Autoimmunity and Cancer via Human Dendritic Cell Subsets
Upstream Regulation of Autoimmunity and Cancer via Human Dendritic Cell Subsets
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
*
Daniel J. Cua,
Merck Research Laboratories, USA
Drew M. Pardoll,
Johns Hopkins University School of Medicine, USA
Checkpoint Inhibition
Checkpoint Inhibition
Alan J. Korman,
Bristol-Myers Squibb, USA
Immune Checkpoint Blockade and Adverse Events in Mice, Cynos and Man
Immune Checkpoint Blockade and Adverse Events in Mice, Cynos and Man
Coffee Break
Emmett V. Schmidt,
Merck Research Labs, USA
Developing Combination Strategies using PD-1 Checkpoint Inhibitors to Treat Cancer
Developing Combination Strategies using PD-1 Checkpoint Inhibitors to Treat Cancer
Robert L. Coffman,
Dynavax Technologies, USA
Expanding the Potential of Cancer Immunotherapy with TLR9 Agonists
Expanding the Potential of Cancer Immunotherapy with TLR9 Agonists
Leonardo Ferreira,
University of California, San Francisco, USA
Short Talk: Chimeric Antigen Receptors for Dissecting Treg Biology and Next-Gen Treg Therapy
Short Talk: Chimeric Antigen Receptors for Dissecting Treg Biology and Next-Gen Treg Therapy
Lisa Cucolo,
University of Pennsylvania, USA
Tumor RIPK1 Signaling Mediates Intrinsic and Extrinsic Mechanisms of Resistance to Immune Checkpoint Blockade Therapy
Tumor RIPK1 Signaling Mediates Intrinsic and Extrinsic Mechanisms of Resistance to Immune Checkpoint Blockade Therapy
17:00—18:45
Integrated Themes across Preclinical and Clinical Treatment of Cancer and Autoimmunity
Registered attendees can view abstracts starting on 01/18/2019
Registered attendees can view abstracts starting on 01/18/2019
*
Maria Grazia Roncarolo,
Stanford University School of Medicine, USA
Mark J. Smyth,
QIMR Berghofer Medical Research Institute, Australia
The Role of CD39 in the Immunological Control of Cancer
The Role of CD39 in the Immunological Control of Cancer
Daniel J. Cua,
Merck Research Laboratories, USA
Applying Lessons from Autoimmune Inflammation to Immuno-Oncology
Applying Lessons from Autoimmune Inflammation to Immuno-Oncology
Hergen Spits,
University of Amsterdam, Netherlands
Harnessing the Power of the Immune System for Therapy: Past Present and Future
Harnessing the Power of the Immune System for Therapy: Past Present and Future
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Registered attendees can view abstracts starting on 01/18/2019
Registered attendees can view abstracts starting on 01/18/2019
*
Hergen Spits,
University of Amsterdam, Netherlands
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
